EULAV Asset Management’s DexCom DXCM Stock Holding History

EULAV Asset Management’s Portfolio DXCM Stock Details DXCM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-27,000	Closed	-$1.82M	–	149
2025 Q3	$1.82M	Sell	27,000 -16	-0.1%	-$1.27K	0.04%	153
2025 Q2	$2.36M	Buy	27,016 +1	+0%	+$78	0.06%	154
2025 Q1	$1.84M	Sell	27,015 -21,985	-45%	-$1.79M	0.05%	160
2024 Q4	$3.81M	Sell	49,000 -32,000	-40%	-$2.37M	0.09%	142
2024 Q3	$5.43M	Buy	81,000 +5,986	+8%	+$492K	0.13%	129
2024 Q2	$8.51M	Sell	75,014 -13,999	-16%	-$1.77M	0.23%	106
2024 Q1	$12.3M	Sell	89,013 -8,987	-9%	-$1.13M	0.34%	81
2023 Q4	$12.2M	Sell	98,000 -2,000	-2%	-$204K	0.38%	75
2023 Q3	$9.33M	Buy	100,000 +21,938	+28%	+$2.47M	0.34%	82
2023 Q2	$10M	Sell	78,062 -10,938	-12%	-$1.32M	0.37%	73
2023 Q1	$10.3M	Buy	89,000 +3,000	+3%	+$336K	0.41%	67
2022 Q4	$9.74M	Sell	86,000 -36,000	-30%	-$3.95M	0.42%	68
2022 Q3	$9.83M	Buy	122,000 +10,000	+9%	+$847K	0.43%	69
2022 Q2	$8.35M	Buy	112,000 +36,000	+47%	+$3.29M	0.34%	81
2022 Q1	$9.72M	Sell	76,000 -24,000	-24%	-$2.63M	0.29%	96
2021 Q4	$13.4M	Sell	100,000 -56,000	-36%	-$8.05M	0.34%	87
2021 Q3	$21.3M	Sell	156,000 -48,000	-24%	-$6.05M	0.56%	63
2021 Q2	$21.8M	Buy	204,000 +40,000	+24%	+$3.84M	0.58%	67
2021 Q1	$14.7M	Hold	164,000	–	–	0.39%	84
2020 Q4	$15.2M	Buy	164,000 +16,000	+11%	+$1.43M	0.4%	89
2020 Q3	$15.3M	Sell	148,000 -2,000	-1%	-$209K	0.45%	76
2020 Q2	$15.2M	Sell	150,000 -52,000	-26%	-$4.65M	0.5%	67
2020 Q1	$13.6M	Sell	202,000 -54,000	-21%	-$3.36M	0.54%	65
2019 Q4	$14M	Sell	256,000 -36,000	-12%	-$1.71M	0.48%	73
2019 Q3	$10.9M	Sell	292,000 -124,000	-30%	-$4.82M	0.4%	79
2019 Q2	$15.6M	Buy	416,000 +152,000	+58%	+$4.78M	0.58%	57
2019 Q1	$7.6M	Hold	264,000	–	–	0.31%	93
2018 Q4	$7.91M	Sell	264,000 -36,000	-12%	-$1.14M	0.4%	83
2018 Q3	$10.7M	Sell	300,000 -20,000	-6%	-$620K	0.46%	74
2018 Q2	$7.6M	Sell	320,000 -4,000	-1%	-$84.8K	0.35%	91
2018 Q1	$6.01M	Sell	324,000 -84,000	-21%	-$1.24M	0.29%	116
2017 Q4	$5.85M	Sell	408,000 -32,000	-7%	-$416K	0.28%	126
2017 Q3	$5.38M	Buy	440,000 +80,000	+22%	+$1.41M	0.25%	131
2017 Q2	$6.58M	Buy	360,000 +28,000	+8%	+$517K	0.32%	109
2017 Q1	$7.03M	Sell	332,000 -48,000	-13%	-$937K	0.36%	93
2016 Q4	$5.67M	Buy	+380,000	New	+$6.73M	0.31%	114
2016 Q2	–	Sell	-54,000	Closed	-$917K	–	278
2016 Q1	$917K	Hold	54,000	–	–	0.05%	249
2015 Q4	$1.11M	Buy	+54,000	New	+$1.12M	0.06%	253

Other funds holding DXCM

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JSC

J. Stern & Co London, United Kingdom $1.03B AUM 20.71% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

EULAV Asset Management's DXCM Position: Q4 2025 in Review

EULAV Asset Management sold out of DexCom (DXCM) in Q4 2025, closing a stake of 27,000 shares — an estimated $1.82M sold.

EULAV Asset Management first reported a position in DXCM in Q4 2015 and held it in 38 quarters. The position peaked at $21.8M in Q2 2021. 921 funds tracked by Wall St. Rank hold DXCM as of Q4 2025.

EULAV Asset Management reported no remaining DexCom position as of Q4 2025 after selling out during the quarter.
EULAV Asset Management sold 27,000 DexCom shares in Q4 2025, an estimated $1.82M.
EULAV Asset Management first reported a position in DexCom in Q4 2015 and held it in 38 quarters.
EULAV Asset Management's DexCom position peaked at $21.8M in Q2 2021.
921 funds tracked by Wall St. Rank held DexCom as of Q4 2025.

Based on EULAV Asset Management's 13F filing for Q4 2025, filed 11 Feb 2026.